AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01783457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual psychoeducation
Description: Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request.
Study NCT01687192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV prophylactic vaccine Gardasil
Description: 3 injections: at Inclusion visit then 2 and 6 months after.
Study NCT00607516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented primary bipolar hemiarthroplasty of the hip
Description: Cemented primary bipolar hemiarthroplasty of the hip
Study NCT00607516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented primary bipolar hemiarthroplasty of the hip
Description: Uncemented primary bipolar hemiarthroplasty of the hip
Study NCT02350361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin 7.5mg/m2
Study NCT02350361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02353611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide
Study NCT01579539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
Study NCT04205994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: FMRI provides an indirect and noninvasive measure of brain activity.
Study NCT04205994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: FMRI provides an indirect and noninvasive measure of brain activity.
Study NCT01206868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fenestration
Description: Fenestration of the peritoneum according to the length of the transplanted kidney
Study NCT01206868 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard kidney transplantation
Study NCT01504568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment
Description: Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
Study NCT02353611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35% hydrogen peroxide
Description: conventional peroxide whitening compound acted like control
Study NCT02467153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RET
Description: RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months.
Study NCT02467153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally as tablets; 1 tablet per day for 6 months.
Study NCT02467153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
Study NCT02324335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilacidin
Description: Oral Rinse used 3 times daily for 7 weeks
Study NCT02324335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02179190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BARREL VRD
Description: The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
Study NCT00288704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rilonacept 160 mg
Description: Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
Study NCT00288704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
Study NCT00288704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rilonacept 160 mg
Description: Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
Study NCT02578290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default.
Study NCT02673008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
Study NCT01460992 — intervention group
Intervention type: PROCEDURE
Intervention: Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions
Description: patients will undergo an MRI scan for 30 minutes.
Study NCT02133274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychosocial Intervention
Description: Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
Study NCT02133274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
Study NCT01759121 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: T-PRP
Description: 532nm-short pulse panretinal photocoagulation with PASCAL function
Study NCT01759121 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: S-PRP
Description: 532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
Study NCT03386461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
Study NCT03386461 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
Study NCT03386461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3 supplementation
Description: Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
Study NCT03386461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
Study NCT03825198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Study NCT03825198 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector spinae plane block
Description: Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,25%
Description: 20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
Study NCT03282851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11456
Description: Subjects will receive a single injection of MSB11456 on Day 1.
Study NCT03282851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Actemra
Description: Subjects will receive a single injection of US-licensed actemra on Day 1.
Study NCT03825198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spine fusion
Description: fusion of lumbar vertebral body on 1 or two levels
Study NCT03282851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra
Description: Subjects will receive a single injection of EU-approved RoActemra on Day 1.
Study NCT01579539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg i.v. infusion once a week for 12 weeks
Study NCT03825198 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: spine fusion
Description: fusion of lumbar vertebral body on 1 or two levels
Study NCT00961766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00010 (Neublastin)
Description: Single dose, weight-based IV administration
Study NCT00961766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV matched placebo
Study NCT04226534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maximal effort test
Description: Performing a maximal effort test on the treadmill
Study NCT01519570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Description: The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
Study NCT01543373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amphilimus Eluting Stent
Description: Sirolimus formulated coronary eluting stent
Study NCT01543373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Bare metal coronary stent
Study NCT03773211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renaparin
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
Study NCT03773211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
Study NCT02145988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Study NCT02145988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Study NCT01601431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap Assisted Colonoscopy
Description: Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
Study NCT01601431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy
Description: Regular colonoscopy as per standard clinical guidelines
Study NCT03480906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Latanoprost ophthalmic solution administered as a microdose spray
Study NCT03480906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost ophthalmic solution administered as an eyedrop
Study NCT00925990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
Study NCT00925990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: 5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
Study NCT00925990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsules identical to ribavirin in appearance containing inactive ingredients
Study NCT04418284 — intervention group
Intervention type: OTHER
Intervention: survey
Description: online survey
Study NCT02016430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MeLT Dietary intervention
Description: Mediterranean diet containing food with low TMAO content.
Study NCT02016430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC Dietary intervention
Description: Standard American Heart Association (AHA) recommendations for dietary counseling.
Study NCT02016430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MeLT dietary intervention with TMAO
Description: Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
Study NCT05093478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal capsaicin
Description: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
Study NCT05093478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical lidocaine
Description: The nose will be pre-treated with topical lidocaine 15 minutes before each application
Study NCT03690453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: single dose of Ivermectin
Study NCT00645684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Anastomosis
Description: Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
Study NCT02687178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canrenone 50 vs canrenone 100 mg
Study NCT01867112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity either by individualized program or general guidelines
Study NCT03964844 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02091219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2400 IU/day by mouth for 16 weeks
Study NCT02091219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25(OH)D3
Description: 20 micrograms/day by mouth for 16 weeks
Study NCT00234910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: TDF 300mg QD for 72 wks
Study NCT00234910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir with 2 Nucleoside RTIs
Description: LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
Study NCT00234910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir with 2 Nucleoside RTIs
Description: LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
Study NCT01257802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot leuprolide acetate 3.75 mg
Description: Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
Study NCT01257802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
Study NCT03674424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Chemotherapy with or without avelumab followed by surgery
Study NCT03674424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystectomy
Description: Cystectomy 3 to 6 weeks after last administration of chemotherapy
Study NCT03674424 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CG
Description: Chemotherapy 4 cycles of 3 weeks
Study NCT03674424 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DD-MVAC
Description: Chemotherapy 4 cycles of 2 weeks
Study NCT03674424 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PG
Description: Chemotherapy 2 cycles of 4 weeks
Study NCT02829918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
Study NCT03708068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early exclusive enteral nutrition
Description: Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
Study NCT04636086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Vitamin D supplementation
Study NCT04636086 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04284748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercise with blood flow restriction
Description: Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: NaCL 0,9%
Description: 20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Study NCT04284748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric exercise
Description: Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
Study NCT04284748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy program
Description: Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises